- AGENT III研究
- 幻灯语言：英文
- 幻灯大小：27KB
- 幻灯类型：PPT
- 发布时间：2007-11-21 8:10:57
- 应用平台：Win9x/Me/NT/2000/XP
- 相关网站：internet
-
- 版权说明：本站所有资源来源于网络，版权为原作者所有，本站刊载，仅限于促进医药行业发展、科技进步之目的。如本站行为侵犯了您的合法权益，请来信
告知，我们将妥善处理。给您带来不便，敬请原谅。 - 幻灯介绍：
Ad5FGF-4 gene
Adenoviral intracoronary infusion of human angiogenic fibroblast growth factor-4 (FGF-4)
Primary Endpoint:
Exercise tolerance test time compared with baseline at 12 weeks, 6 months and 1 year.
Secondary Endpoints:
Time to number of patients with coronary events and death at 12 months
Time to ST depression, angina, and quality of life parameters
AGENT III: 12 week results
Presented at TCT 2004
PlaceboLow-dose
High-dose
415 patients with CCS Class 2-4 angina not in need of urgent revascularization
AGENT III Trial: 12 week results
The 12-week results show no difference between the three groups in the primary endpoint – mean change in exercise duration from baseline
seconds
TCT 2004
Mean change in exercise duration from baseline to 12 weeks
p=ns
AGENT III: 12-week results
415 people with stable angina were randomized to receive placebo or a low- or high-dose intracoronary infusion of an adenoviral gene for fibroblast growth factor-4 (FGF-4) before the trial was stopped earlier this year by the data safety and monitoring board
The 12-week results show no difference between the three groups in the primary endpoint – mean change in exercise duration from baseline.
TCT 2004
